Cyclin D1 Overexpression versus Response to Induction Chemotherapy in Squamous Cell Carcinoma of the Head and Neck?Preliminary Report

References

• Weaver A, Fleming S, Ensley J, et al. Superior clinical response and survival rates with initial bolus of cisplatin and 120 hours infusion of 5-fluorouracil before definitive therapy for locally advanced head and neck cancer. Am J Surg 1984; 148: 525–9.
   PubMed Web of Science ®Google Scholar
• Rooney M, Kish J, Jacobs J, et al. Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hours 5-FU infusion and cisplatin. Cancer 1985; 55: 1123–8.
   PubMed Web of Science ®Google Scholar
• Jacobs C, Makuch R. Efficacy of adjuvant chemotherapy for patients with resectable head and neck cancer: a subset analy-sis of the head and neck contracts program. J Clin Oncol 1990; 8: 838–47.
   PubMed Web of Science ®Google Scholar
• The Department of Veterans' Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryn-geal cancer. N Engl J Med 1991; 324: 1685–1690.
   Google Scholar
• Forastiere A. Randomized trials of induction chemotherapy. A critical review. Haematol Oncol Clin North Am 1991; 5: 725–36.
   PubMed Web of Science ®Google Scholar
• Haas J, Toohill R, Haas C, et al. The effect of delaying standard treatment for induction chemotherapy in advanced head and neck cancer. Am J Clin Oncol (CCT) 1987; 10: 116.
   Google Scholar
• Rosenthal D, Pistenmaa D, Glatsein E. A review of neoadju-vant chemotherapy for head and neck cancer: partially shrunken tumors may be both leaner and meaner. Int J Radiat Oncol Biol Phys 1994; 28: 315–20.
   Google Scholar
• Loehrer P, Einhom L. Drugs five years later. Cisplatin. Ann Intern Med 1984; 100: 704–13.
   PubMed Web of Science ®Google Scholar
• Robben N, Pippas A, Moore J. The syndrome of 5-fluorou-racil cardiotoxicity. Cancer 1993; 71: 493–509.
   Google Scholar
• Schantz S, Savage H, Brown B, et al. Association of levels of circulating Cl q binding macromolecules with induction chemotherapy response in head and neck cancer patients. Cancer Res 1988; 48: 5868–73.
   PubMedGoogle Scholar
• Ensley J, Maciorowski Z, Pietraszkievic H. Methodology and clinical applications of flow cytometry in squamous cell car-cinomas of the head and neck. In: Jacobs C, ed. Carcinomas of the Head, and Neck. Evaluation and Management. Boston: Kluwer Academic Publishers, 1990: 225–42.
   Google Scholar
• Tennvall J, Wennerberg J, Anderson H, et al. DNA analysis as a predictor of the outcome of induction chemotherapy in advanced head and neck carcinomas. Arch Otolaryngol Head Neck Surg 1993; 119: 867–70.
   PubMedGoogle Scholar
• Bradford C, Zhu S, Wolf G, et al. Overexpression of p53 predicts organ preservation using induction chemotherapy and radiation in patients with advanced larygeal cancer. Oto-laryngol Head Neck Surg 1995; 113: 334–9.
   PubMedGoogle Scholar
• Lewin F, Skog S, Tribukait B, et al. Effect of combined treatment with cisplatin and 5-fluorouracil on cell growth and cell cycle kinetics of a mouse ascites tumor growing. In Vivo 1990; 4: 277–82.
   PubMedGoogle Scholar
• Fantl V, Richards M, Smith R, et al. Gene amplification on chromosome band 11q13 and oestrogen receptor status in breast cancer. Eur J Cancer 1990; 26: 423–9.
   PubMed Web of Science ®Google Scholar
• Jiang W, Hahn S, Tomita N, et al. Amplification and expres-sion of human cyclin D gene in esophageal cancer. Cancer Res 1992; 52: 2980–3.
   PubMed Web of Science ®Google Scholar
• Tsuruta H, Sakamoto H, Onda M, et al. Amplification and overexpression of EXP I and EXP2/cyclin DI genes in human esophageal carcinomas. Biochem Biophys Res Commun 1993; 196: 1529–36.
   PubMedGoogle Scholar
• Lammie G, Fantl V, Smith R, et al. D115287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene 1991; 6: 439–44.
   PubMedGoogle Scholar
• Akervall J, Michalides R, Mineta H, et al. Amplification of cyclin DI in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin DI overexpression. Cancer 1997; 79: 380–9.
   PubMed Web of Science ®Google Scholar
• Michalides R, Van Veelen N, Hart A, et al. Overexpression of cyclin DI correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res 1995; 55: 975–8.
   PubMedGoogle Scholar
• Bartokova J, Lukas J, Muller H, et al. Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Res 1995; 55: 949–56.
   PubMed Web of Science ®Google Scholar
• Hermanek P, Sobin LH, (eds.) TNM classification of malig-nant tumours. 4th, fully revised, ed. Berlin: Springer Verlag, 1987.
   Google Scholar
• Haeder H, Rosenberg B. Inhibitory effects of anti-tumor platinum compounds on DNA, RNA and protein syntheses in mammalian cells in vitro. Int .1- Cancer 1970; 6: 207–16.
   PubMedGoogle Scholar
• Howle J, Gale G. Cis-dichlorodiammineplatinum (II). Persis-tent and selective inhibition deoxyribonucleic acid synthesis in vivo. Biochem Pharmacol 1970; 19: 2757–62.
   Google Scholar
• Danenberg P, Montag B, Heidelberger C. Studies on fluori-nated pyramidines, W. Effects on nucleic acid metabolism in vivo. Cancer Res 1958; 18: 329–34.
   Google Scholar
• Lewin F, Skog S, Ringborg U. Effect of 5-fluorouracil on the cell growth and cell cycle kinetics of a mouse ascites tumor growing in vivo. Acta Oncol 1987; 26: 125–31.
   Google Scholar
• Warenius H, Saebra A, Maw P. Sensitivity to cis-di-amminedichloroplatinum in human cancer cells is related to expression of cyclin D1 but not c-raf-1 protein. Int .1- Cancer 1996; 67: 224–31.
   Google Scholar
• Bailey B. Beyond the 'new' TNM classification. Arch Otolar-yngol Head Neck Surg 1991; 117: 369–70.
   PubMedGoogle Scholar